Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms

Abstract The pediatric lysosomal storage disorder mucopolysaccharidosis type II is caused by mutations in IDS, resulting in accumulation of heparan and dermatan sulfate, causing severe neurodegeneration, skeletal disease, and cardiorespiratory disease. Most patients manifest with cognitive symptoms,...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Hélène FE Gleitz, Ai Yin Liao, James R Cook, Samuel F Rowlston, Gabriella MA Forte, Zelpha D'Souza, Claire O'Leary, Rebecca J Holley, Brian W Bigger
Format:	Artigo
Jezik:	Inglês
Izdano:	Springer Nature 2018-06-01
Serija:	EMBO Molecular Medicine
Teme:	apolipoprotein E blood–brain barrier Hunter mucopolysaccharidosis type II stem cell gene therapy
Online dostop:	https://doi.org/10.15252/emmm.201708730
Oznake:	Označite Brez oznak, prvi označite!